Importantly, this synergistic effect is particularly pronounced in TLR4-positive MDA-MB-231 breast cancer cells, while the effect is less evident in HCC1806 cells that lack TLR4, underscoring the critical role of TLR4 in the therapeutic combination of hyperoside and paclitaxel. This evidence concerns the gene TLR4 and breast cancer.